Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million to acquire the intellectual property (IP) rights of gatipotuzumab, an antitumor-associated mucin-1 (TA-MUC1) antibody, from Germany-headquartered Glycotope GmbH. This strategic acquisition strengthens Daiichi Sankyo’s portfolio in cancer therapy.
Acquisition Details and Background
Daiichi Sankyo obtained global exclusive development and manufacturing rights to gatipotuzumab via a licensing deal with Glycotope in 2018. The recent payment of USD 132.5 million fulfills the terms of this agreement, securing the IP rights and furthering the company’s commitment to advancing innovative cancer treatments.
TA-MUC1: Target and Therapeutic Potential
TA-MUC1 is a tumor-specific transmembrane glycoprotein with aberrant glycosylation due to changes in the expression patterns of some sialyltransferases. This characteristic makes it an attractive target for cancer therapy. Currently, there are no TA-MUC1-targeted therapies approved for any type of cancer, highlighting the potential of gatipotuzumab to address significant unmet medical needs.
DS-3939: Investigational ADC
DS-3939, an investigational potential first-in-class TA-MUC1 directed antibody drug conjugate (ADC), is being studied in Phase I/II trials. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-3939 is being evaluated in multiple advanced solid tumors, including non-small cell lung cancer, breast cancer, urothelial cancer, ovarian cancer, biliary cancer, and pancreatic cancer. This ADC represents a promising approach to targeted cancer therapy, leveraging the unique properties of TA-MUC1.
Strategic Implications
The acquisition of gatipotuzumab’s IP rights by Daiichi Sankyo underscores the company’s dedication to advancing its oncology pipeline. By securing the rights to this innovative antibody and developing DS-3939, Daiichi Sankyo aims to contribute to the global effort to develop more effective cancer treatments. This move is expected to enhance the company’s position in the competitive oncology market and bring new hope to patients with various types of cancer.-Fineline Info & Tech
Leave a Reply